BSP:N1VO34 (Denmark)
Business Description
Novo Nordisk A/S
Novo Alle 1, Bagsvaerd, DNK, DK-2880
Compare
Compare
Traded in other countries / regions
NNOR.Austria
•
N1VO34.Brazil
•
NOVO B.Denmark
•
NOVA.Germany
•
NVO.Mexico
•
NOVOB.Switzerland
•
0QIU.UK
•
NVO.USA
Description
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.22 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 0.34 | |||||
| Debt-to-EBITDA | 0.34 | |||||
| Interest Coverage | 15.7 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 9.26 | |||||
| Beneish M-Score | -2.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.8 | |||||
| 3-Year EBITDA Growth Rate | 10.1 | |||||
| 3-Year EPS without NRI Growth Rate | 9.2 | |||||
| 3-Year FCF Growth Rate | 15.9 | |||||
| 3-Year Book Growth Rate | 13.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 15.36 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 11.59 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.4 | |||||
| 9-Day RSI | 24.17 | |||||
| 14-Day RSI | 31.46 | |||||
| 6-1 Month Momentum % | 11.06 | |||||
| 12-1 Month Momentum % | 9.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.94 | |||||
| Quick Ratio | 0.74 | |||||
| Cash Ratio | 0.28 | |||||
| Days Inventory | 286.78 | |||||
| Days Sales Outstanding | 80.62 | |||||
| Days Payable | 134.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.44 | |||||
| Dividend Payout Ratio | 0.06 | |||||
| 3-Year Dividend Growth Rate | 6 | |||||
| Forward Dividend Yield % | 2.4 | |||||
| 5-Year Yield-on-Cost % | 1.52 | |||||
| 3-Year Average Share Buyback Ratio | 1.9 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 83.92 | |||||
| Operating Margin % | 42.24 | |||||
| Net Margin % | 32.14 | |||||
| ROE % | 73.58 | |||||
| ROA % | 26.8 | |||||
| ROIC % | 29.72 | |||||
| ROC (Joel Greenblatt) % | 121.57 | |||||
| ROCE % | 70.43 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 34.19 | |||||
| Forward PE Ratio | 31.45 | |||||
| PE Ratio without NRI | 34.19 | |||||
| Shiller PE Ratio | 45.68 | |||||
| Price-to-Owner-Earnings | 31.65 | |||||
| PEG Ratio | 4.88 | |||||
| PS Ratio | 10.99 | |||||
| PB Ratio | 22.99 | |||||
| Price-to-Tangible-Book | 57.09 | |||||
| Price-to-Free-Cash-Flow | 29.94 | |||||
| Price-to-Operating-Cash-Flow | 26.16 | |||||
| EV-to-EBIT | 25.38 | |||||
| EV-to-Forward-EBIT | 23.29 | |||||
| EV-to-EBITDA | 23.07 | |||||
| EV-to-Forward-EBITDA | 21.37 | |||||
| EV-to-Revenue | 10.84 | |||||
| EV-to-Forward-Revenue | 9.92 | |||||
| EV-to-FCF | 29.56 | |||||
| Price-to-Projected-FCF | 3.08 | |||||
| Price-to-DCF (Earnings Based) | 0.18 | |||||
| Price-to-DCF (FCF Based) | 1.54 | |||||
| Price-to-Median-PS-Value | 1.43 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4.24 | |||||
| Price-to-Graham-Number | 9.33 | |||||
| Earnings Yield (Greenblatt) % | 3.94 | |||||
| Forward Rate of Return (Yacktman) % | 10.32 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 123,250.595 | ||
| EPS (TTM) (R$) | 17.277 | ||
| Beta | 0 | ||
| Volatility % | 28.24 | ||
| 14-Day RSI | 31.46 | ||
| 14-Day ATR (R$) | 1.738797 | ||
| 20-Day SMA (R$) | 74.838 | ||
| 12-1 Month Momentum % | 9.91 | ||
| 52-Week Range (R$) | 60.72 - 83.44 | ||
| Shares Outstanding (Mil) | 2,262.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novo Nordisk A/S Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||